Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-08-19

Clinical Trial Update: A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase [Phase 3]

View source ↗

Summary

Phase 3 trial update on imatinib and nilotinib in chronic myeloid leukemia in chronic phase; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Imatinib (imatinib)
  • Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2019-08-19